comparemela.com

Latest Breaking News On - Nucleic acids on demand world wide - Page 1 : comparemela.com

Manufacture your own DNA the easy way

DNA Script Advances Evaluation Program for the SYNTAX System, the First Benchtop DNA Printer Powered By Enzymatic Synthesis

DNA Script Advances Evaluation Program for the SYNTAX System, the First Benchtop DNA Printer Powered By Enzymatic Synthesis USA - English Share this article Share this article The SYNTAX System Delivers DNA On Demand to Enable Labs to Control Their Workflow, Innovate Faster SOUTH SAN FRANCISCO, Calif., and PARIS, May 20, 2021 /PRNewswire/  DNA Script, a leading pioneer in enabling enzymatic DNA synthesis on demand, today announced the third and final phase of its evaluation program for the SYNTAX System, the world s first benchtop printer powered by Enzymatic DNA Synthesis (EDS) technology. This SYNTAX instrument is designed to require less than 15 minutes of hands-on setup and synthesize DNA in as little as six hours, producing 96 ready-to-use oligos in parallel. 

DNA Script Partners with Moderna to Develop On-Demand Vaccines and Therapeutics for DARPA

DNA Script Partners with Moderna to Develop On-Demand Vaccines and Therapeutics for DARPA
zazoom.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from zazoom.it Daily Mail and Mail on Sunday newspapers.

Ximedica announces partnership with Moderna, Inc (Nasdaq: MRNA) to develop a prototype for rapid mobile manufacturing of vaccines

Share this article Share this article PROVIDENCE, R.I., March 31, 2021 /PRNewswire/  Ximedica today announced a partnership with Moderna, Inc. (Nasdaq: MRNA) to develop a prototype for rapid mobile manufacturing of vaccines and therapeutics as part of the Defense Advanced Research Projects Agency s (DARPA) Nucleic Acids On-Demand World-Wide (NOW) Program. Integrating Moderna s proprietary mRNA technology with Ximedica s instrument design and engineering expertise, both teams will work closely together in an effort to meet capability expectations set out by the DARPA program over the 4-year partnership. As part of the agreement, Ximedica will receive up to $11 million in funding. DARPA s Nucleic Acids On-Demand World-Wide initiative aims to develop a mobile, just-in-time manufacturing platform that quickly diagnoses pathogen threats and provides medical countermeasures to deliver pandemic prevention treatments in-field. The resulting Good Manufacturing Practice (GMP) quality mRN

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.